Emisphere Message Board - Msg: 17471717

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Emisphere

EMIS 10.01

+0.6%

Jan 15 3:50 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Miljenko Zuanic who wrote (170)	5/15/2002 1:07:00 PM
From: Cacaito	Read Replies (1) of 272

News are misreporting some aspects of the Emis trial. Lovenox and the other low molecular heparins are superior to regular heparin. Less testing of coagulation tests are needed, very low incidence of the HIT syndrome, easier titration (or none). Lovenox is very expensive. Emis strategy (I just learnt from the report) was risky and now they are paying for it. Emis did not compare Oral vs against regular heparin... Emis did not compare oral vs coumadin chronic type of use... Emis did not try to show oral/Lovenox equivalency... Emis went for the 3 pointer, attempting to show their Oral heparin was superior to injectable SC Lovenox, that was the problem. Emis oral heparin DOES WORK, but the news is that there was failure to work, the only failure was not showing superiority to Lovenox. But, it could have been that the FDA force them to try against the best therapy (I have no evidence for this) and that is why they chose that strategy. Emis oral delivery technology does work for heparin (complex carbohydrate), if it will work for peptides and large proteins is a different story, but their animal models show it does work. Good company for Elan to swallow, Elan likes orphans and widows.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next